Abstract
METHOD: Three specific developments in the field of schizophrenia are highlighted: advances in knowledge related to the earliest stages of schizophrenia, specifically the prodrome; reconceptualization of schizophrenia as an illness of multiple symptom domains; and greater clarification regarding the efficacy of clozapine and a new generation of APs.
RESULTS: Evidence indicating that negative and cognitive symptoms are present during the prodrome suggests that intervention at the time of first-episode psychosis constitutes late intervention. The limited efficacy of APs beyond psychosis argues against a magic bullet approach to schizophrenia and for polypharmacy that is symptom domain-specific. Clozapine's unique, but limited, efficacy in treatment resistance supports subtyping schizophrenia based on treatment response.
CONCLUSIONS: Advances in our understanding of schizophrenia have important implications regarding the current use of APs, expectations regarding response, and future drug development.
OBJECTIVE: To examine how advances in our understanding of schizophrenia have shaped thinking about antipsychotics (APs) and their role in treatment.
| Original language | English |
|---|---|
| Pages (from-to) | S14-S18 |
| Journal | Canadian journal of psychiatry. Revue canadienne de psychiatrie |
| Volume | 60 |
| Issue number | 3 |
| Publication status | Published - 2015 Mar 1 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
What does schizophrenia teach us about antipsychotics? / Remington, Gary; Agid, Ofer; Foussias, George; Fervaha, Gagan; Takeuchi, Hiroyoshi; Lee, Jimmy; Hahn, Margaret.
In: Canadian journal of psychiatry. Revue canadienne de psychiatrie, Vol. 60, No. 3, 01.03.2015, p. S14-S18.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - What does schizophrenia teach us about antipsychotics?
AU - Remington, Gary
AU - Agid, Ofer
AU - Foussias, George
AU - Fervaha, Gagan
AU - Takeuchi, Hiroyoshi
AU - Lee, Jimmy
AU - Hahn, Margaret
PY - 2015/3/1
Y1 - 2015/3/1
N2 - METHOD: Three specific developments in the field of schizophrenia are highlighted: advances in knowledge related to the earliest stages of schizophrenia, specifically the prodrome; reconceptualization of schizophrenia as an illness of multiple symptom domains; and greater clarification regarding the efficacy of clozapine and a new generation of APs.RESULTS: Evidence indicating that negative and cognitive symptoms are present during the prodrome suggests that intervention at the time of first-episode psychosis constitutes late intervention. The limited efficacy of APs beyond psychosis argues against a magic bullet approach to schizophrenia and for polypharmacy that is symptom domain-specific. Clozapine's unique, but limited, efficacy in treatment resistance supports subtyping schizophrenia based on treatment response.CONCLUSIONS: Advances in our understanding of schizophrenia have important implications regarding the current use of APs, expectations regarding response, and future drug development.OBJECTIVE: To examine how advances in our understanding of schizophrenia have shaped thinking about antipsychotics (APs) and their role in treatment.
AB - METHOD: Three specific developments in the field of schizophrenia are highlighted: advances in knowledge related to the earliest stages of schizophrenia, specifically the prodrome; reconceptualization of schizophrenia as an illness of multiple symptom domains; and greater clarification regarding the efficacy of clozapine and a new generation of APs.RESULTS: Evidence indicating that negative and cognitive symptoms are present during the prodrome suggests that intervention at the time of first-episode psychosis constitutes late intervention. The limited efficacy of APs beyond psychosis argues against a magic bullet approach to schizophrenia and for polypharmacy that is symptom domain-specific. Clozapine's unique, but limited, efficacy in treatment resistance supports subtyping schizophrenia based on treatment response.CONCLUSIONS: Advances in our understanding of schizophrenia have important implications regarding the current use of APs, expectations regarding response, and future drug development.OBJECTIVE: To examine how advances in our understanding of schizophrenia have shaped thinking about antipsychotics (APs) and their role in treatment.
UR - http://www.scopus.com/inward/record.url?scp=85018719316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018719316&partnerID=8YFLogxK
M3 - Review article
C2 - 25886675
AN - SCOPUS:85018719316
VL - 60
SP - S14-S18
JO - Canadian Journal of Psychiatry
JF - Canadian Journal of Psychiatry
SN - 0706-7437
IS - 3
ER -